Welcome to our dedicated page for KESTRA MED TECHNOLOGIES news (Ticker: KMTS), a resource for investors and traders seeking the latest updates and insights on KESTRA MED TECHNOLOGIES stock.
News for Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) focuses on its activities as a commercial-stage wearable medical device and digital healthcare company in cardiovascular care. Company announcements highlight developments related to its Cardiac Recovery System platform and ASSURE Wearable Cardioverter Defibrillator (ASSURE WCD), as well as financial performance and capital markets activity.
Investors and clinicians following KMTS news will see updates on clinical evidence, including communications about the ASSURE WCD Clinical Evaluation Post-Approval Study (ACE-PAS), which Kestra describes as the largest prospective real-world study of wearable defibrillators to date. Press releases detail study design and key endpoints such as shock conversion success, inappropriate shock rates, wear time, and detection of additional arrhythmias in diverse cardiac recovery populations.
Kestra’s news flow also includes information on strategic collaborations, such as its agreement with Biobeat Technologies, Ltd. to integrate FDA-cleared, cuffless ambulatory blood pressure monitoring into the ASSURE WCD ecosystem. These items explain how additional diagnostic data, like 24-hour blood pressure measurements, may expand the clinical insights available for patients prescribed the wearable defibrillator.
Financial and corporate updates are another key component of KMTS coverage. The company issues press releases on quarterly financial results, preliminary revenue and margin trends, and public offerings of common shares. It also announces participation in major healthcare and investor conferences, including cardiology meetings and investment bank conferences, where management presents Kestra’s strategy and platform.
This news page aggregates these disclosures so readers can track Kestra’s clinical milestones, technology integrations, financial updates, and conference appearances in one place. For ongoing research into KMTS, users can review both operational announcements and regulatory communications as they are released.
Kestra Medical Technologies (Nasdaq: KMTS) was named a finalist for the 2026 GeekWire Awards “Deal of the Year” for its successful 2025 initial public offering. The recognition cites impactful transactions and highlights Kestra’s expanding Pacific Northwest presence and commercial growth of its Cardiac Recovery System®.
Community voting runs through April 16, 2026, with winners announced at the GeekWire Awards ceremony on May 7, 2026 in Seattle.
Kestra Medical Technologies (Nasdaq: KMTS) reported Q3 FY2026 results for the period ended January 31, 2026, with $24.6M revenue (+63% YoY) and gross margin expanding to 52.6% from 43.4%. The company raised FY26 revenue guidance to $93M (up 55% YoY) and reported $291M cash.
Operational highlights included 5,462 ASSURE prescriptions (+58%), an equity offering closed Dec 4, 2025, and adjusted EBITDA loss of $21.2M.
Kestra Medical Technologies (Nasdaq: KMTS) will report third quarter fiscal 2026 results on Tuesday, March 17, 2026 with a conference call at 4:30 p.m. ET. A live and archived webcast will be available in the investor relations Events section; participants are asked to register 10 minutes early.
Kestra Medical Technologies (Nasdaq: KMTS) announced a strategic collaboration and exclusive license/co-development with Biobeat to integrate Biobeat’s FDA-cleared, cuffless 24-hour ambulatory blood pressure monitoring (ABPM) into the ASSURE Wearable Cardioverter Defibrillator (WCD) ecosystem.
The agreement includes a $5 million equity investment in Biobeat’s Series B and aims to provide continuous, noninvasive blood pressure data to support at-home cardiac recovery. Kestra cited its ACE-PAS study where 72% of patients were hypertensive, underscoring the partnership’s clinical relevance for guideline-directed medical therapy optimization.
Kestra Medical Technologies (NASDAQ: KMTS) will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 2:15 p.m. PT.
Investors and interested parties can access a live webcast and replay via the company's investor relations website.
Kestra Medical Technologies (Nasdaq: KMTS) reported Q2 FY2026 results for the period ended October 31, 2025: revenue $22.6M (+53% YoY), ASSURE prescriptions 4,696 (+54% YoY), and gross margin 50.6% (vs 39.6% prior year). GAAP net loss was $32.8M and adjusted EBITDA loss was $19.7M. Kestra raised FY26 revenue guidance to $91M (+52% vs FY25). Cash and cash equivalents were $175M as of Oct 31, 2025; the company also received $148M net proceeds from a Dec 4, 2025 public offering.
The company cited commercial expansion, improved revenue cycle management, and a stronger in-network mix as drivers of performance.
Kestra Medical Technologies (Nasdaq: KMTS) will report second quarter fiscal 2026 financial results on Thursday, December 11, 2025. Management will host a conference call at 4:30 p.m. Eastern Time with a live and archived webcast available in the investor relations "Events" section. Participants are encouraged to register on the website at least 10 minutes prior to the call start.
Kestra Medical Technologies (Nasdaq: KMTS) priced an upsized underwritten public offering of 6,000,000 common shares at $23.00 per share, producing expected gross proceeds of $138,000,000.
The company granted the underwriters a 30-day option to buy up to 900,000 additional shares at the offering price less discounts. The offering is expected to close on December 4, 2025, subject to customary closing conditions. A registration statement was declared effective on December 2, 2025.
Kestra Medical Technologies (Nasdaq: KMTS) announced a proposed underwritten public offering of 5,500,000 common shares with a 30-day underwriter option to purchase up to an additional 825,000 shares, subject to market conditions and SEC effectiveness of the registration statement (as of Dec 1, 2025).
The company intends to use proceeds to support sales and marketing, ongoing commercialization, further fund research, development and clinical studies, and for working capital and general corporate purposes. All offered shares are being sold by Kestra. Bookrunners include BofA Securities, Piper Sandler, J.P. Morgan, Goldman Sachs and Wells Fargo Securities. The offering may not occur and terms may change.
Kestra Medical Technologies (Nasdaq: KMTS) reported preliminary Q2 fiscal 2026 results for the quarter ended October 31, 2025, showing continued commercial momentum in the wearable defibrillator market. Revenue is expected to be $22.2–$22.6M, up ~52% at the midpoint versus prior year. Gross profit is expected to be $11.0–$11.4M and gross margin is expected near 50.0% versus 39.6% prior year. Loss from operations is expected to be $31.6–$32.0M. Cash and cash equivalents are expected to be approximately $175M. Results are preliminary and subject to adjustment; final results will appear in the Form 10-Q filed in December 2025.